CYTOKINETICS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
William Blair initiated coverage on Cytokinetics (NASDAQ:CYTK) with an Outperform rating and $101 price target, citing 58% upside potential. The firm expects commercial launch of MYQORZO by 2027 and $3.74B sales by 2032. Other analysts maintain bullish views, while the company faces legal action against Bristol-Myers Squibb and MyoKardia.
UBS reduced its price target for Cytokinetics (CYTK) to $104 from $115 but kept a Buy rating. The stock trades at $61.62, below the revised target and analyst consensus. UBS sees potential in Cytokinetics' drugs for hypertrophic cardiomyopathy. The company's shares have underperformed recently, down 7% in six months. Cytokinetics reported Q2 Myqorzo sales of $25.3M, exceeding estimates. Barclays raised its target to $110, while other analysts maintained Buy ratings with higher targets.
Cytokinetics (CYTK) reported new data from ACACIA-HCM trial showing aficamten improved exercise performance and safety. The company plans to submit a supplemental NDA to the FDA this quarter. According to the company, the data supports efficacy and safety.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning CYTK (CYTOKINETICS INC). Coverage has skewed bullish: 6 bullish, 0 neutral, and 2 bearish.
Recent CYTK coverage spans financial news and sector analysis.
In the last 30 days, CYTK insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($8.3M). The most active reporter was Blum Robert I, President & CEO, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst initiation and a high price target suggest bullish sentiment and potential buying pressure.
The target cut suggests the market may re‑price CYTK lower, increasing downside risk.
Positive trial data and upcoming sNDA submission are likely to boost investor sentiment.
The insider sale may create short-term selling pressure.
The announcements may generate short‑term interest but no immediate catalyst; impact depends on forthcoming data.
AlphAI scores every news story that mentions CYTK with an AI model for sentiment and relevance, and aggregates insider trades from CYTOKINETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
William Blair initiated coverage on Cytokinetics (NASDAQ:CYTK) with an Outperform rating and $101 price target, citing 58% upside potential. The firm expects commercial launch of MYQORZO by 2027 and $3.74B sales by 2032. Other analysts maintain bullish views, while the company faces legal action against Bristol-Myers Squibb and MyoKardia.
2 min readUBS reduced its price target for Cytokinetics (CYTK) to $104 from $115 but kept a Buy rating. The stock trades at $61.62, below the revised target and analyst consensus. UBS sees potential in Cytokinetics' drugs for hypertrophic cardiomyopathy. The company's shares have underperformed recently, down 7% in six months. Cytokinetics reported Q2 Myqorzo sales of $25.3M, exceeding estimates. Barclays raised its target to $110, while other analysts maintained Buy ratings with higher targets.
2 min readCytokinetics (CYTK) reported new data from ACACIA-HCM trial showing aficamten improved exercise performance and safety. The company plans to submit a supplemental NDA to the FDA this quarter. According to the company, the data supports efficacy and safety.
1 min readCytokinetics (CYTK) EVP Fady Malik sold 3,500 shares for $214,830 at $61.38 each, holding 153,902 shares. He also exercised options for 3,500 shares at $7.8 each. CYTK, valued at $8.75B, reported $25.3M in Myqorzo sales, beating estimates. Analysts have strong buy consensus with targets up to $146. The company faces legal action against Bristol-Myers and MyoKardia.
1 min readCytokinetics (CYTK) announced four presentations at the HFSA Annual Scientific Meeting 2026, including two late-breaking clinical trial results for aficamten in non-obstructive hypertrophic cardiomyopathy. The company plans to submit a Supplemental New Drug Application for aficamten in Q4 2026, following positive topline results from the ACACIA-HCM trial.
1 min readCytokinetics (CYTK) launched ASPEN-HCM, a real-world study evaluating MYQORZO (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The study, led by UCSF, will track safety, clinical effectiveness, and healthcare resource impact in 400 patients over 12-36 months. MYQORZO, a cardiac myosin inhibitor, is approved for oHCM treatment but carries a heart failure risk.
2 min readB. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
3 min readCytokinetics (CYTK) EVP Fady Malik sold 3,500 shares for $239,015 and exercised options for 3,500 more. The company reported $25.3M in Myqorzo sales, beating estimates. Barclays raised its price target to $110. Analysts maintain positive ratings, with targets up to $140.
1 min readCytokinetics Inc (CYTK) Director Robert Landry sold 1,000 shares on 2026-09-15, reducing his holding to 8,184 shares. The sale occurred at $72.13 per share, with the company's market cap at $9.64 billion. Over the past year, Landry sold 2,000 shares and bought none, aligning with a broader trend of 79 insider sells and 0 buys. GuruFocus values CYTK at $220.41, suggesting a possible value trap with a 0.33 price-to-GF-Value ratio.
2 min readA trust for Cytokinetics (CYTK) CEO Robert I. Blum filed a Rule 144 notice to sell 97,926 shares, valued at $7.1M, on NASDAQ by September 15, 2026. The shares were acquired as equity compensation between 2024 and 2026.
1 min read
